Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more
Genolution Inc. (225220) - Net Assets
Latest net assets as of September 2025: ₩73.39 Billion KRW
Based on the latest financial reports, Genolution Inc. (225220) has net assets worth ₩73.39 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩99.84 Billion) and total liabilities (₩26.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩73.39 Billion |
| % of Total Assets | 73.51% |
| Annual Growth Rate | 48.34% |
| 5-Year Change | 30.99% |
| 10-Year Change | N/A |
| Growth Volatility | 734.7 |
Genolution Inc. - Net Assets Trend (2016–2024)
This chart illustrates how Genolution Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genolution Inc. (2016–2024)
The table below shows the annual net assets of Genolution Inc. from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩80.29 Billion | -8.19% |
| 2023-12-31 | ₩87.45 Billion | -7.65% |
| 2022-12-31 | ₩94.70 Billion | +15.20% |
| 2021-12-31 | ₩82.20 Billion | +34.12% |
| 2020-12-31 | ₩61.29 Billion | +2222.78% |
| 2019-12-31 | ₩2.64 Billion | -10.22% |
| 2018-12-31 | ₩2.94 Billion | -26.55% |
| 2017-12-31 | ₩4.00 Billion | +16.85% |
| 2016-12-31 | ₩3.42 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genolution Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5954828751000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩56.72 Billion | 70.64% |
| Common Stock | ₩9.60 Billion | 11.95% |
| Other Components | ₩13.97 Billion | 17.41% |
| Total Equity | ₩80.29 Billion | 100.00% |
Genolution Inc. Competitors by Market Cap
The table below lists competitors of Genolution Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stardust Power Inc.
NASDAQ:SDST
|
$15.94 Million |
|
Plantynet Co. Ltd
KQ:075130
|
$15.94 Million |
|
Zaigle Co. Ltd
KQ:234920
|
$15.94 Million |
|
Transindia Real Estate Limited
NSE:TREL
|
$15.94 Million |
|
Albert David Limited
NSE:ALBERTDAVD
|
$15.92 Million |
|
Teract S.A.
PA:TRACT
|
$15.92 Million |
|
Fondia Oyj
HE:FONDIA
|
$15.91 Million |
|
Pharmx Technologies Ltd
AU:PHX
|
$15.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genolution Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 87,449,947,580 to 80,288,111,530, a change of -7,161,836,050 (-8.2%).
- Net loss of 6,825,574,710 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-6.83 Billion | -8.5% |
| Other Changes | ₩-336.26 Million | -0.42% |
| Total Change | ₩- | -8.19% |
Book Value vs Market Value Analysis
This analysis compares Genolution Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.99x to 0.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩603.01 | ₩1806.00 | x |
| 2017-12-31 | ₩683.78 | ₩1806.00 | x |
| 2018-12-31 | ₩462.34 | ₩1806.00 | x |
| 2019-12-31 | ₩438.77 | ₩1806.00 | x |
| 2020-12-31 | ₩6406.41 | ₩1806.00 | x |
| 2021-12-31 | ₩4496.32 | ₩1806.00 | x |
| 2022-12-31 | ₩5246.02 | ₩1806.00 | x |
| 2023-12-31 | ₩4843.25 | ₩1806.00 | x |
| 2024-12-31 | ₩4446.61 | ₩1806.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genolution Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -95.65%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.33x
- Recent ROE (-8.50%) is below the historical average (16.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 2.57% | 5.87% | 0.38x | 1.17x | ₩-254.36 Million |
| 2017 | 14.42% | 23.66% | 0.52x | 1.18x | ₩176.92 Million |
| 2018 | 43.96% | 41.26% | 0.28x | 3.78x | ₩998.16 Million |
| 2019 | -10.88% | -7.26% | 0.29x | 5.09x | ₩-550.86 Million |
| 2020 | 52.28% | 37.57% | 1.02x | 1.37x | ₩25.92 Billion |
| 2021 | 41.84% | 47.22% | 0.77x | 1.15x | ₩26.17 Billion |
| 2022 | 15.42% | 38.34% | 0.33x | 1.21x | ₩5.13 Billion |
| 2023 | -6.35% | -56.86% | 0.09x | 1.30x | ₩-14.30 Billion |
| 2024 | -8.50% | -95.65% | 0.07x | 1.33x | ₩-14.85 Billion |
Industry Comparison
This section compares Genolution Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $259,224,420,269
- Average return on equity (ROE) among peers: -0.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genolution Inc. (225220) | ₩73.39 Billion | 2.57% | 0.36x | $15.93 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |